Sep 07, 2023 / 05:50PM GMT
Samantha Lynn Semenkow - Citigroup Inc., Research Division - VP
Hello, everyone. Thank you for joining us for our cell therapy autoimmune panel. I'm Sam Semenkow, one of the biotech analysts here at Citi. I'm joined with my colleague, Yigal Nochomovitz on the end. It's my pleasure to have with us today, Gwen Binder, she is the President of Science and Tech at Cabaletta; Pascal Touchon, CEO and President of Atara Bio; and Kevin Xie, CEO and President of Gracell. CFO, I'm sorry. CFO.
Well, thank you for all joining us today for what I hope will be a lively panel. So just to kick it off, perhaps we could just go down the line. If you could all give a very brief like 1 to 2 summary of your company and what you're working on.
Gwendolyn K. Binder - Cabaletta Bio, Inc. - President of Science & Technology
Yes, thanks. Really a pleasure to be here. Cabaletta Bio is a clinical stage biotechnology company. We're focused -- since we were founded in 2018 and since the beginning, we've been focused on developing targeted curative therapies for patients with
Gracell Biotechnologies Inc at Citi BioPharma Conference Transcript
Sep 07, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers